Improved glycaemic control in people with type 2 diabetes initiating or switching to insulin degludec/insulin aspart (IDegAsp) in a real‐world setting in China
Authors' conclusion
In a broad, real-world Chinese population of adults with T2D, initiating or switching to IDegAsp was associated with improved glycaemic control and lower rates of hypoglycaemia. The use of IDegAsp could be an effective treatment option for those with suboptimal glycaemic control or therapeutic inertia.
Study context
- Population
- Chinese adults with T2D initiating, or switching to IDegAsp after treatment with oral antidiabetic drugs (OADs), other insulins, or GLP-1 RA
- Participants
- 878 adults
- Outcome
- Change in HbA1c from baseline to end of study
- Follow-up
- 20 weeks
Methodological detailssingle-arm, open-label, real-world
- Single-arm
- Open-label
- Real-world
Main finding
As reported in the abstract
Change in HbA1c, overall population
−1.27%-points
95% CI −1.36; −1.19p < 0.0001
Observational data: associations, not effects.
Secondary outcomes
Change in fasting plasma glucose from baseline · end of study
- Change in FPG, overall population
- −1.61 mmol/L (95% CI: −1.81; −1.41; p < 0.0001)
HbA1c and FPG in subgroups switching from OADs only, or basal, or premix insulins ± OADs
- Significant reductions in HbA1c and FPG in these subgroups
Mean total Diabetes Treatment Satisfaction Questionnaire (DTSQ) score · baseline to end of study
- Mean total DTSQ score, baseline
- 26.4
- Mean total DTSQ score, end of study
- 31.6
Safety
Hypoglycaemic episodes
- Non-severe hypoglycaemia incidence rate ratio
- 0.37 (95% CI: 0.24; 0.59; p < 0.0001)
- Nocturnal non-severe hypoglycaemia incidence rate ratio
- 0.45 (95% CI: 0.21; 0.94; p = 0.0326)
Tolerability and safety
- No significant, or unexpected tolerability, or safety issues were observed
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →